Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia

1CNS Network, Inc., Garden Grove, CA; 2Desert Pacific Mental Illness Research, Education, and Clinical Center UCLA Semel Institute for Neuroscience, Los Angeles, CA; 3Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY; 4Department for Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria; 5Schizophrenia Research Group, Psychiatry & Behavioral Sciences, Division of Medical Psychology, School of Medicine, Duke University, Durham, NC; 6Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC